Auxier Asset Management Biogen Inc. Transaction History

Auxier Asset Management

$628 Million
Q2 2024

A detailed history of Auxier Asset Management transactions in Biogen Inc. stock. As of the latest transaction made, Auxier Asset Management holds 16,220 shares of BIIB stock, worth $2.82 Million. This represents 0.6% of its overall portfolio holdings.

Number of Shares

16,220

Previous 16,605 2.32%

Holding current value

$2.82 Million

Previous $3.58 Million 5.03%

% of portfolio

0.6%

Previous 0.55%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$190.52 - $236.72 $73,350 - $91,137	-385 Reduced 2.32%	16,220 $3.76 Million
Q1 2024 May 08, 2024	SELL	$212.02 - $267.71 $1.07 Million - $1.35 Million	-5,053 Reduced 23.33%	16,605 $3.58 Million
Q4 2023 Feb 22, 2024	SELL	$222.59 - $267.94 $22,704 - $27,329	-102 Reduced 0.47%	21,658 $5.6 Million
Q3 2023 Nov 21, 2023	SELL	$253.3 - $285.89 $6,332 - $7,147	-25 Reduced 0.11%	21,760 $5.59 Million
Q2 2023 Aug 17, 2023	SELL	$275.25 - $318.06 $140,377 - $162,210	-510 Reduced 2.29%	21,785 $6.21 Million
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $12,828 - $14,616	-50 Reduced 0.22%	22,295 $6.2 Million
Q4 2022 Feb 17, 2023	SELL	$252.44 - $306.72 $342,056 - $415,605	-1,355 Reduced 5.72%	22,345 $6.19 Million
Q3 2022 Nov 15, 2022	SELL	$194.69 - $268.46 $7,787 - $10,738	-40 Reduced 0.17%	23,700 $6.33 Million
Q2 2022 Aug 11, 2022	SELL	$187.54 - $223.02 $13,127 - $15,611	-70 Reduced 0.29%	23,740 $4.84 Million
Q4 2021 Mar 01, 2022	SELL	$223.92 - $287.77 $39,186 - $50,359	-175 Reduced 0.73%	23,810 $5.71 Million
Q3 2021 Nov 18, 2021	SELL	$282.99 - $369.05 $41,033 - $53,512	-145 Reduced 0.6%	23,985 $6.79 Million
Q2 2021 Aug 18, 2021	SELL	$259.0 - $414.71 $61,383 - $98,286	-237 Reduced 0.97%	24,130 $8.36 Million
Q1 2021 May 17, 2021	SELL	$242.95 - $284.63 $4,859 - $5,692	-20 Reduced 0.08%	24,367 $6.82 Million
Q4 2020 Mar 05, 2021	BUY	$236.26 - $355.63 $28,351 - $42,675	120 Added 0.49%	24,387 $5.97 Million
Q3 2020 Mar 05, 2021	SELL	$264.77 - $305.71 $11,914 - $13,756	-45 Reduced 0.19%	24,267 $6.88 Million
Q2 2020 Aug 20, 2020	SELL	$258.66 - $342.55 $504,387 - $667,972	-1,950 Reduced 7.43%	24,312 $6.51 Million
Q1 2020 May 15, 2020	SELL	$268.85 - $341.04 $310,521 - $393,901	-1,155 Reduced 4.21%	26,262 $8.31 Million
Q3 2019 Nov 15, 2019	BUY	$217.44 - $243.88 $43,488 - $48,776	200 Added 0.73%	27,417 $6.38 Million
Q2 2019 Aug 15, 2019	BUY	$219.29 - $241.72 $210,518 - $232,051	960 Added 3.66%	27,217 $6.37 Million
Q1 2019 May 14, 2019	BUY	$216.71 - $338.96 $21,671 - $33,896	100 Added 0.38%	26,257 $6.21 Million
Q4 2018 Feb 13, 2019	SELL	$278.5 - $352.75 $557,000 - $705,500	-2,000 Reduced 7.1%	26,157 $7.87 Million
Q2 2018 Aug 15, 2018	SELL	$257.52 - $306.91 $17,511 - $20,869	-68 Reduced 0.24%	28,157 $8.17 Million
Q1 2018 May 14, 2018	BUY	$260.13 - $367.91 $18,209 - $25,753	70 Added 0.25%	28,225 $7.73 Million
Q4 2017 Feb 14, 2018	BUY	$307.64 - $344.58 $3,076 - $3,445	10 Added 0.04%	28,155 $8.97 Million
Q3 2017 Nov 09, 2017	SELL	$281.15 - $329.69 $7,028 - $8,242	-25 Reduced 0.09%	28,145 $8.81 Million
Q2 2017 Aug 16, 2017	BUY	N/A	28,170	28,170 $7.64 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Auxier Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Auxier Asset Management with notifications on news.

Account

Auxier Asset Management Biogen Inc. Transaction History